Promising cancer drug trial halted early: what it means for patients
NCT ID NCT06478862
First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 27 times
Summary
This study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if the drug could slow cancer growth and be safe. The trial was ended early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rambam Health Care Campus
Haifa, Israel
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shamir Medical Center (Asaf Harofeh)
Ẕerifin, 70300, Israel
-
Soroka Medical Center
Beersheba, Israel
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Wolfson Medica Center
Holon, 5822012, Israel
Conditions
Explore the condition pages connected to this study.